课题基金 / 基金详情

HYPONATREMIA OF MALIGNANCY

HYPONATREMIA OF MALIGNANCY
恶性肿瘤低钠血症
批准号:
6163433
负责人:
B E JOHNSON
金额:
$0.0万
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:
至

项目摘要

项目成果

B E JOHNSON的其他基金

相似基金

相关文献

中文摘要
翻译
“停产”。肺癌生物学 已经进行了两项前瞻性试验,以研究 精氨酸加压素和心钠素的异位生产 肺癌患者体内的多肽含量。这些研究是 确定这些荷尔蒙对钠的影响 动态平衡以及肾素、血管紧张素和醛固酮 系统。50例,31例小细胞肺癌,19例 非小细胞肺癌参与了最初的临床试验。 11名患者出现低钠血症;10名患者出现较小的 细胞性肺癌(32%)和1例非小细胞肺癌 癌症。所有11名出现低钠血症的患者都有 AVP水平不适当地升高。血浆AVP升高 低钠血症的发生率与血钠水平高度相关(p<0.05)。
英文摘要
"""DISCONTINUED"". The Lung Cancer Biology Section has undertaken two prospective trials to study the role of ectopic production of arginine vasopressin and atrial natriuretic peptide in 64 patients with lung cancer. These studies were undertaken to define the impact of these hormones on sodium homeostasis as well as the renin, angiotensin, and aldosterone system. Fifty patients, 31 with small cell lung cancer and 19 with non-small cell lung cancer participated in the initial clinical trial. Eleven patients presented with hyponatremia; 10 patients with small cell lung cancer (32%) and 1 patient with non-small cell lung cancer. All 11 patients who presented with hyponatremia had inappropriately elevated levels of AVP. Elevated plasma AVP levels were highly correlated with the presence of hyponatremia (p"
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
IN VITRO DRUG TESTING FOR LIMITED SCLC AND PHASE I DRUG DEVELOPMENT
  • 批准号:
    3939554
  • 项目类别:
  • 资助金额:
    $0.0万
  • 财政年份:
    --
  • 负责人:
    B E JOHNSON
  • 依托单位:
MOLECULAR GENETIC EVENTS IN LUNG CANCER
  • 批准号:
    3838085
  • 项目类别:
  • 资助金额:
    $0.0万
  • 财政年份:
    --
  • 负责人:
    B E JOHNSON
  • 依托单位:
IN VITRO DRUG TESTING FOR LIMITED SCLC AND PHASE I DRUG DEVELOPMENT
  • 批准号:
    3853211
  • 项目类别:
  • 资助金额:
    $0.0万
  • 财政年份:
    --
  • 负责人:
    B E JOHNSON
  • 依托单位:
IN VITRO DRUG TESTING FOR LIMITED SCLC AND PHASE I DRUG DEVELOPMENT
  • 批准号:
    3916620
  • 项目类别:
  • 资助金额:
    $0.0万
  • 财政年份:
    --
  • 负责人:
    B E JOHNSON
  • 依托单位:
海外基金